Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.

Huang M, Garcia JS, Thomas D, Zhu L, Nguyen LX, Chan SM, Majeti R, Medeiros BC, Mitchell BS.

Oncotarget. 2016 Nov 15;7(46):74917-74930. doi: 10.18632/oncotarget.12493.

2.

DDX6 transfers P-TEFb kinase to the AF4/AF4N (AFF1) super elongation complex.

Mück F, Bracharz S, Marschalek R.

Am J Blood Res. 2016 Sep 15;6(3):28-45. eCollection 2016.

3.

TBP loading by AF4 through SL1 is the major rate-limiting step in MLL fusion-dependent transcription.

Okuda H, Takahashi S, Takaori-Kondo A, Yokoyama A.

Cell Cycle. 2016 Oct 17;15(20):2712-22. doi: 10.1080/15384101.2016.1222337. Epub 2016 Aug 26.

4.

Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.

Alicea-Velázquez NL, Shinsky SA, Loh DM, Lee JH, Skalnik DG, Cosgrove MS.

J Biol Chem. 2016 Oct 21;291(43):22357-22372. Epub 2016 Aug 25.

5.

An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.

Patel AV, Chaney KE, Choi K, Largaespada DA, Kumar AR, Ratner N.

EBioMedicine. 2016 Jul;9:110-119. doi: 10.1016/j.ebiom.2016.06.007. Epub 2016 Jun 4.

6.

Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair.

Castaño J, Herrero AB, Bursen A, González F, Marschalek R, Gutiérrez NC, Menendez P.

Oncotarget. 2016 May 24;7(21):30440-52. doi: 10.18632/oncotarget.8938.

7.

Systematic Classification of Mixed-Lineage Leukemia Fusion Partners Predicts Additional Cancer Pathways.

Marschalek R.

Ann Lab Med. 2016 Mar;36(2):85-100. doi: 10.3343/alm.2016.36.2.85. Review.

8.

AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.

Ahmad K, Scholz B, Capelo R, Schweighöfer I, Kahnt AS, Marschalek R, Steinhilber D.

Oncotarget. 2015 Sep 22;6(28):25784-800. doi: 10.18632/oncotarget.4703.

9.

AF4 and AF4N protein complexes: recruitment of P-TEFb kinase, their interactome and potential functions.

Scholz B, Kowarz E, Rössler T, Ahmad K, Steinhilber D, Marschalek R.

Am J Blood Res. 2015 Jun 15;5(1):10-24. eCollection 2015.

10.

Unraveling the Activation Mechanism of Taspase1 which Controls the Oncogenic AF4-MLL Fusion Protein.

Sabiani S, Geppert T, Engelbrecht C, Kowarz E, Schneider G, Marschalek R.

EBioMedicine. 2015 Apr 16;2(5):386-95. doi: 10.1016/j.ebiom.2015.04.009. eCollection 2015 May.

11.

Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.

Rao RC, Dou Y.

Nat Rev Cancer. 2015 Jun;15(6):334-46. doi: 10.1038/nrc3929. Review.

12.

Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL.

Ahmad K, Katryniok C, Scholz B, Merkens J, Löscher D, Marschalek R, Steinhilber D.

Oncogenesis. 2014 Nov 17;3:e127. doi: 10.1038/oncsis.2014.39.

13.

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.

Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G.

Blood. 2014 Mar 13;123(11):1729-38. doi: 10.1182/blood-2013-03-489575. Epub 2014 Jan 21.

14.

Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.

Ballabio E, Milne TA.

Cancers (Basel). 2012 Sep 10;4(3):904-44. doi: 10.3390/cancers4030904.

15.

The MLL recombinome of acute leukemias in 2013.

Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cavé H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, Cazzaniga G, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schäfer BW, Kubetzko S, Alonso CN, zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Möricke A, Stanulla M, Schrappe M, Sedék L, Szczepański T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grümayer R, Dingermann T, Klingebiel T, Marschalek R.

Leukemia. 2013 Nov;27(11):2165-76. doi: 10.1038/leu.2013.135. Epub 2013 Apr 30.

16.

Epigenetic therapy of hematological malignancies: where are we now?

Popovic R, Shah MY, Licht JD.

Ther Adv Hematol. 2013 Apr;4(2):81-91. doi: 10.1177/2040620712466864.

17.

Inhibition of HIV-1 transcription and replication by a newly identified cyclin T1 splice variant.

Gao G, Wu X, Zhou J, He M, He JJ, Guo D.

J Biol Chem. 2013 May 17;288(20):14297-309. doi: 10.1074/jbc.M112.438465. Epub 2013 Apr 8.

18.

RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.

Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, Biswas D, Roeder RG, Allis CD, Melnick A, de Bruijn MF, Milne TA.

Cell Rep. 2013 Jan 31;3(1):116-27. doi: 10.1016/j.celrep.2012.12.016. Epub 2013 Jan 24.

19.

Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics.

Copeland RA, Moyer MP, Richon VM.

Oncogene. 2013 Feb 21;32(8):939-46. doi: 10.1038/onc.2012.552. Epub 2012 Nov 19. Review.

20.

Identification of novel CDK9 and Cyclin T1-associated protein complexes (CCAPs) whose siRNA depletion enhances HIV-1 Tat function.

Ramakrishnan R, Liu H, Donahue H, Malovannaya A, Qin J, Rice AP.

Retrovirology. 2012 Oct 30;9:90. doi: 10.1186/1742-4690-9-90.

Supplemental Content

Support Center